M&A Deal Summary |
|
|---|---|
| Date | 2013-11-11 |
| Target | ViroPharma |
| Sector | Life Science |
| Buyer(s) | Shire |
| Deal Type | Add-on Acquisition |
| Deal Value | 4.2B USD |
| Advisor(s) | Skadden, Arps, Slate, Meagher & Flom (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1986 |
| Sector | Life Science |
| Employees | 5,548 |
| Revenue | 6.4B USD (2015) |
Shire plc is a global specialty biopharmaceutical company. Shire plc strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 16 |
| Sector (Life Science) | 7 of 15 |
| Type (Add-on Acquisition) | 6 of 14 |
| State (Pennsylvania) | 1 of 1 |
| Country (United States) | 6 of 13 |
| Year (2013) | 2 of 2 |
| Size (of disclosed) | 4 of 12 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-03-25 |
SARcode Bioscience
Brisbane, California, United States SARcode Bioscience Inc. is a biopharmaceutical company based in Brisbane, California. |
Buy | $160M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-01-17 |
Dermagraft
Canton, Massachusetts, United States Dermagraft is a provider of nonhealing diabetic foot ulcers. Dermagraft is headquartered in Canton, Massachusetts. |
Sell | - |
